Jay Horowitz, MD
Otolaryngology · East Brunswick, NJNPI 1255421673
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.3%), food and beverage and education — rather than concentrated in one kind of arrangement. Optinose US, Inc. accounts for 65.7% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2021 at $2,097 and has fallen 80.3% since, to $412 in 2025.
Across 128 payments — averaging $31.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Optinose US, Inc.$3K
- Sanofi$555
- Regeneron Healthcare Solutions, Inc.$232
- GSK$146
- Kaleo, Inc.$91
- Lilly USA, LLC$60
- plus $307 from 11 others
What the payments were for
- Consulting fees$2,00049%
- Food & beverage$1,97149%
- Education$832%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Optinose US, Inc. | 47 | $2,663 |
| Sanofi | 33 | $555 |
| Regeneron Healthcare Solutions, Inc. | 14 | $232 |
| GSK | 10 | $146 |
| Kaleo, Inc. | 5 | $91 |
| Lilly USA, LLC | 3 | $60 |
| Penumbra, Inc. | 1 | $53 |
| Sanofi-aventis U.S. LLC | 1 | $53 |
| Alk-abello, Inc | 3 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $32 |
| AbbVie | 2 | $30 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| LEO Pharma Inc. | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $13 |
| Boehringer Ingelheim | 1 | $12 |
| Novartis | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xhance$2,000
How this compares
$4,054 in reported general payments places this provider in the 85th percentile of 232 otolaryngology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XhanceFluticasone Propionate | 53 | $43,229 |
| Ipratropium Bromide | 753 | $21,799 |
| Azelastine Hcl | 419 | $10,162 |
| Mometasone Furoate | 89 | $7,271 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 28 | $6,508 |
| DexilantDexlansoprazole | 12 | $4,222 |
| Olopatadine Hcl | 33 | $3,509 |
| Fluticasone Propionate | 136 | $1,993 |
| Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth | 13 | $1,340 |
| Levocetirizine Dihydrochloride | 87 | $1,249 |
| Pantoprazole Sodium | 57 | $893 |
| Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort | 15 | $717 |
| Cefdinir | 40 | $658 |
| Ofloxacin | 36 | $605 |
| Montelukast Sodium | 37 | $522 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Optinose US, Inc.Xhance | $2,663 | $43,22953 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Dexilant | $32 | $4,22212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 232 otolaryngology providers in New Jersey.
Other otolaryngology in East Brunswick
- Kenneth KaplanEast Brunswick$3K
- Kimberly RethyEast Brunswick$3K
- Nishant ReddyEast Windsor$133K
- Giant LinFlorham Park$25K
- Samir ShahVoorhees$16K
- Brian BensonHackensack$14K
- Andrew BlitzerHackensack$9K
- Ahmad MahmoudClifton$9K
- Jean EloyNewark$8K
- Ramtin KassirWayne$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.